RECOMMENDATION:
The NDA #20-358 that was filed on February 28, 1994 for bupropion HCL (WELLBUTRIN®) 50, 100, and 150 mg sustained release (SR) tablets has been found to meet the Division of Biopharmaceutics’ requirements.
Please forward the above Recommendation and Comments 5 and 6 to the firm.
Table of Contents |
Page # |
Synopsis |
1 |
Recommendation |
2 |
Background |
4 |
Summary
of Bioavailability/Bioequivalence Studies |
6 |
Comments |
|
|
|
APPENDIX I (Summary of Study Reports): |
|
Pilot or Background Studies |
|
Study 96: Steady-State
Pharmacokinetics of Two Daily Oral
Doses of WELLBUTRIN® and Its Basic Metabolites in Normal Volunteers.
|
14 |
Study 201: Single-Dose
Bioequivalence of WELLBUTRIN® Immediate Release Tablets in Healthy Male
Volunteers.
|
20 |
Study 204: A
Single-Dose Bioavailability Evaluation of the 50 and 100 mg WELLBUTRIN®
Sustained Release Tablets in Healthy Male Volunteers.
|
28 |
Pivotal Bioavailability/Bioequivalence Studies: |
|
Study 202: A
Single-Dose Bioequivalence/Effect of Food Evaluation of WELLBUTRIN® Sustained
Release.
|
33 |
Study 206: Steady-State
Bioequivalence Evaluation of Bupropion Sustained Release and Bupropion
Immediate Release Tablets in Healthy Male Volunteers.
|
40 |
Study 207: A
Bioequivalency Study of 50, 100, and 150 mg Bupropion Sustained Release
Tablets in Healthy Male Volunteers.
|
48 |
Dissolution |
56 |
3
Back a Page
Next Page
Back to Wellbutrin SR. NDA Index Page
Back to Main
Index